RNA in situ hybridization market seen rising to $2.49 billion by 2030

The global RNA in situ hybridization market is projected to grow from $1.49 billion in 2025 to $2.49 billion by 2030, driven by demand for precision oncology, spatial transcriptomics and infectious disease diagnostics. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - RNA in situ hybridization helps detect RNA inside cells and tissue samples without destroying tissue structure. - The technique supports molecular diagnostics, disease diagnosis and personalized medicine. - Market growth reflects rising demand for more precise tools in cancer research, infectious disease testing and genomic analysis.

What happened: - The Business Research Company published its Ribonucleic Acid (RNA) In Situ Hybridization (ISH) Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report estimates the RNA in situ hybridization market will rise from $1.49 billion in 2025 to $1.66 billion in 2026. - The report projects the market will reach $2.49 billion by 2030. - The report implies a 10.7% CAGR over the forecast period. - The company also offered a free sample of the report.

The details: - RNA in situ hybridization uses labeled complementary probes to bind target RNA molecules in cells or tissue samples. - The method enables microscopic examination of gene expression patterns and RNA localization in cellular context. - The report cites growth in cancer biomarker research, molecular biology funding in academia, fluorescence microscopy use, infectious disease diagnostics and early nucleic acid detection as past drivers. - The report points to precision oncology, spatial transcriptomics, personalized medicine, laboratory automation and genomic research investment as future growth drivers. - The report identifies AI-assisted spatial transcriptomics, ultra-sensitive multiplex probes, automated slide hybridization platforms, advanced fluorescent imaging systems and single-cell expression profiling as key technology trends. - The report says infectious disease detection is boosting demand because RNA ISH can pinpoint pathogen-specific RNA in tissue samples while preserving tissue morphology. - The UK Health Security Agency reported 630 confirmed measles cases in England from January to May 2026. - Precision medicine is another driver because RNA ISH can identify RNA biomarkers in tissues and support tailored treatment decisions. - The Personalized Medicine Coalition said the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. - North America led the market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The full report is available online.

Between the lines: - The market outlook suggests RNA ISH is moving from a specialized research tool toward broader clinical use. - Strong growth in precision medicine and spatial biology points to demand for higher-resolution diagnostics and tissue-level molecular data. - Regional growth differences suggest that healthcare investment and research capacity will continue to shape adoption.

What's next: - The market is expected to keep expanding through 2030 as labs adopt more automated and sensitive imaging workflows. - Continued investment in genomic research infrastructure and molecular diagnostics could widen use cases beyond cancer and infectious disease. - The report’s updated analytics and dashboards are aimed at helping buyers and investors track technology and regional opportunities.

The bottom line: - RNA in situ hybridization is becoming more important as medicine shifts toward precise, tissue-level molecular diagnostics and targeted treatment decisions.